SCHEMBL3343560

SCHEMBL3343560

Cc1nc(NNC(=O)c2ccc(-c3ccccc3)cc2)sc1-c1ccc(Br)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.57
KMT2A Q03164 5/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 4/20 0.54
MEN1 O00255 4/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.49
XIAP P98170 2/20 0.48
PIK3CD O00329 1/20 0.48
PIK3CA P42336 1/20 0.48
PIK3CB P42338 1/20 0.48
PIK3CG P48736 1/20 0.48
KDM4E B2RXH2 8/20 0.47
MAPT P10636 7/20 0.47
HTT P42858 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPK1 P28482 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340700 0.88 KDM4E (0.56) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL3341144 0.78 POLB (0.42) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL3341958 0.76 MAPT (0.79) GAAKMT2ARAB9AMEN1KDM4E
SCHEMBL30598987 0.73 KDM4E (0.76) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL26115749 0.73 KDM4E (0.76) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL16607205 0.71 PIK3CD (0.63) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL12992093 0.70 PIK3CG (0.74) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL3338327 0.69 KDM4E (0.61) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL3337610 0.69 KMT2A (0.59) GAAKMT2ANPC1RAB9AMEN1
SCHEMBL3341776 0.69 MAPT (0.89) GAAKMT2AMEN1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA GAA 76/4885KMT2A 3492/4885NPC1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.